Mont-Saint-Guibert, Belgium, February 8, 2024, 10:01 p.m. CET – privileged and regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that the Company will voluntarily file a Form 15F with the United States Securities and Exchange Commission (the “SEC”) to terminate its SEC reporting obligations under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Upon filing of Form 15F, the Company’s reporting obligations with the SEC will be immediately suspended, and the Company will not be required to file an annual report based on Form 20-F for the 2023 fiscal year ending 31 December 2023. The delisting and termination of the Company’s obligation to file reports under the Exchange Act is expected to be final and effective 90 calendar days after the filing of Form 15F, or no sooner than the SEC may determine.
The Company will maintain the listing of its ordinary shares on Euronext Brussels and Euronext Paris.